WO2003022807A3 - Medical devices containing rapamycin analogs - Google Patents

Medical devices containing rapamycin analogs Download PDF

Info

Publication number
WO2003022807A3
WO2003022807A3 PCT/US2002/028776 US0228776W WO03022807A3 WO 2003022807 A3 WO2003022807 A3 WO 2003022807A3 US 0228776 W US0228776 W US 0228776W WO 03022807 A3 WO03022807 A3 WO 03022807A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
drugs
medical devices
carrier
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/028776
Other languages
French (fr)
Other versions
WO2003022807A2 (en
WO2003022807A8 (en
Inventor
Karl W Mollison
Angela M Lecaptain
Sandra E Burke
Keith R Cromack
Peter J Tarcha
Yen-Chih J Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/950,307 external-priority patent/US6890546B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to AT02766269T priority Critical patent/ATE476401T1/en
Priority to AU2002330012A priority patent/AU2002330012B2/en
Priority to EP02766269A priority patent/EP1578705B1/en
Priority to CA2460074A priority patent/CA2460074C/en
Priority to BRPI0212433A priority patent/BRPI0212433A8/en
Priority to DE60237241T priority patent/DE60237241D1/en
Priority to HK06103281.6A priority patent/HK1085723B/en
Priority to JP2003526883A priority patent/JP2006504441A/en
Priority to US10/488,815 priority patent/US7455853B2/en
Priority to JP2004534208A priority patent/JP2005537854A/en
Priority to BR0314013-0A priority patent/BR0314013A/en
Priority to PCT/US2003/007383 priority patent/WO2004022124A1/en
Priority to CA2497640A priority patent/CA2497640C/en
Priority to US10/526,755 priority patent/US20060171984A1/en
Priority to AU2003218077A priority patent/AU2003218077B2/en
Priority to KR1020057003855A priority patent/KR101012605B1/en
Priority to NZ538568A priority patent/NZ538568A/en
Priority to PL03375698A priority patent/PL375698A1/en
Priority to MXPA05002539A priority patent/MXPA05002539A/en
Priority to EP03714060.5A priority patent/EP1536850B1/en
Priority to EP16175557.4A priority patent/EP3175870A1/en
Priority to EP10182123A priority patent/EP2263709A1/en
Publication of WO2003022807A2 publication Critical patent/WO2003022807A2/en
Publication of WO2003022807A8 publication Critical patent/WO2003022807A8/en
Anticipated expiration legal-status Critical
Publication of WO2003022807A3 publication Critical patent/WO2003022807A3/en
Priority to US12/041,537 priority patent/US20080175884A1/en
Priority to US12/041,441 priority patent/US20080145402A1/en
Priority to US12/255,605 priority patent/US20090047324A1/en
Priority to US12/255,603 priority patent/US20090047323A1/en
Priority to US15/091,473 priority patent/US10058641B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43—Hormones, e.g. dexamethasone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to Formula (I). This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.
PCT/US2002/028776 1998-09-24 2002-09-10 Medical devices containing rapamycin analogs Ceased WO2003022807A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
AT02766269T ATE476401T1 (en) 2001-09-10 2002-09-10 MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS
AU2002330012A AU2002330012B2 (en) 2001-09-10 2002-09-10 Medical devices containing rapamycin analogs
EP02766269A EP1578705B1 (en) 2001-09-10 2002-09-10 Medical devices containing rapamycin analogs
CA2460074A CA2460074C (en) 2001-09-10 2002-09-10 Medical devices containing rapamycin analogs
BRPI0212433A BRPI0212433A8 (en) 2001-09-10 2002-09-10 medical devices containing rapamycin analogs
DE60237241T DE60237241D1 (en) 2001-09-10 2002-09-10 MEDICAL DEVICES CONTAINING RAPAMYCINANALOGA
HK06103281.6A HK1085723B (en) 2001-09-10 2002-09-10 Medical devices containing rapamycin analogs
JP2003526883A JP2006504441A (en) 2001-09-10 2002-09-10 Medical devices containing rapamycin analogs
US10/488,815 US7455853B2 (en) 1998-09-24 2002-09-10 Medical devices containing rapamycin analogs
EP10182123A EP2263709A1 (en) 2002-09-06 2003-03-10 Medical device having hydration inhibitor
AU2003218077A AU2003218077B2 (en) 2002-09-06 2003-03-10 Medical device having hydration inhibitor
EP16175557.4A EP3175870A1 (en) 2002-09-06 2003-03-10 Medical device having hydration inhibitor
PCT/US2003/007383 WO2004022124A1 (en) 2002-09-06 2003-03-10 Medical device having hydration inhibitor
CA2497640A CA2497640C (en) 2002-09-06 2003-03-10 Medical device having hydration inhibitor
US10/526,755 US20060171984A1 (en) 2002-09-06 2003-03-10 Device having hydration inhibitor
JP2004534208A JP2005537854A (en) 2002-09-06 2003-03-10 Medical device comprising a hydration inhibitor
KR1020057003855A KR101012605B1 (en) 2002-09-06 2003-03-10 Medical device containing hydration inhibitor
NZ538568A NZ538568A (en) 2002-09-06 2003-03-10 Medical device having hydration inhibitor
PL03375698A PL375698A1 (en) 2002-09-06 2003-03-10 Medical device having a hydration inhibitor
MXPA05002539A MXPA05002539A (en) 2002-09-06 2003-03-10 Medical device having hydration inhibitor.
EP03714060.5A EP1536850B1 (en) 2002-09-06 2003-03-10 Medical device having hydration inhibitor
BR0314013-0A BR0314013A (en) 2002-09-06 2003-03-10 Medical Equipment Containing Hydration Inhibitor
US12/041,441 US20080145402A1 (en) 2001-09-10 2008-03-03 Medical Devices Containing Rapamycin Analogs
US12/041,537 US20080175884A1 (en) 2001-09-10 2008-03-03 Medical Devices Containing Rapamycin Analogs
US12/255,605 US20090047324A1 (en) 2001-09-10 2008-10-21 Medical Devices Containing Rapamycin Analogs
US12/255,603 US20090047323A1 (en) 2001-09-10 2008-10-21 Medical Devices Containing Rapamycin Analogs
US15/091,473 US10058641B2 (en) 2001-09-10 2016-04-05 Medical devices containing rapamycin analogs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/950,307 US6890546B2 (en) 1998-09-24 2001-09-10 Medical devices containing rapamycin analogs
US09/950,307 2001-09-10
US10/235,572 2002-09-06
US10/235,572 US20030129215A1 (en) 1998-09-24 2002-09-06 Medical devices containing rapamycin analogs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/235,572 Continuation-In-Part US20030129215A1 (en) 1997-09-25 2002-09-06 Medical devices containing rapamycin analogs

Related Child Applications (6)

Application Number Title Priority Date Filing Date
US10488815 A-371-Of-International 2002-09-10
US10/488,815 A-371-Of-International US7455853B2 (en) 1998-09-24 2002-09-10 Medical devices containing rapamycin analogs
US12/041,537 Division US20080175884A1 (en) 2001-09-10 2008-03-03 Medical Devices Containing Rapamycin Analogs
US12/041,441 Division US20080145402A1 (en) 2001-09-10 2008-03-03 Medical Devices Containing Rapamycin Analogs
US12/255,605 Division US20090047324A1 (en) 2001-09-10 2008-10-21 Medical Devices Containing Rapamycin Analogs
US12/255,603 Division US20090047323A1 (en) 2001-09-10 2008-10-21 Medical Devices Containing Rapamycin Analogs

Publications (3)

Publication Number Publication Date
WO2003022807A2 WO2003022807A2 (en) 2003-03-20
WO2003022807A8 WO2003022807A8 (en) 2003-12-11
WO2003022807A3 true WO2003022807A3 (en) 2007-06-14

Family

ID=29714851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/028776 Ceased WO2003022807A2 (en) 1998-09-24 2002-09-10 Medical devices containing rapamycin analogs

Country Status (10)

Country Link
US (6) US20030129215A1 (en)
EP (2) EP2255836B1 (en)
JP (1) JP2006504441A (en)
CN (2) CN101564571B (en)
AT (1) ATE476401T1 (en)
BR (1) BRPI0212433A8 (en)
CA (1) CA2460074C (en)
DE (1) DE60237241D1 (en)
PL (1) PL374776A1 (en)
WO (1) WO2003022807A2 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US7651695B2 (en) * 2001-05-18 2010-01-26 Advanced Cardiovascular Systems, Inc. Medicated stents for the treatment of vascular disease
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US7264822B2 (en) * 2002-04-03 2007-09-04 Poly-Med, Inc. Conjugated drug-polymer coated stent
EP2263709A1 (en) * 2002-09-06 2010-12-22 Abbott Laboratories Medical device having hydration inhibitor
BR0316102A (en) 2002-11-07 2005-09-27 Abbott Lab Multiple drug prosthesis in discrete unmixed droplets
US20090093875A1 (en) 2007-05-01 2009-04-09 Abbott Laboratories Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
US8088404B2 (en) * 2003-03-20 2012-01-03 Medtronic Vasular, Inc. Biocompatible controlled release coatings for medical devices and related methods
WO2005016396A1 (en) * 2003-08-13 2005-02-24 Poly-Med, Inc. Biocompatible controlled release coatings for medical devices and related methods
EP1638624B1 (en) * 2003-06-19 2013-10-30 Vascular Therapies, LLC Vascular closure device
AU2004255340B2 (en) * 2003-07-08 2008-05-01 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
US8828416B2 (en) * 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
AU2005222719B2 (en) * 2004-03-19 2011-03-24 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
WO2010048415A1 (en) * 2008-10-22 2010-04-29 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20100021455A1 (en) * 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
TWI455713B (en) * 2005-03-23 2014-10-11 Abbott Lab Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
EP2327429B1 (en) * 2005-03-23 2014-09-17 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
EP3138531A1 (en) 2005-03-23 2017-03-08 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US8003124B2 (en) * 2005-04-08 2011-08-23 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
US8778375B2 (en) * 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US20080214595A1 (en) * 2005-05-16 2008-09-04 Seigo Izumo Use Of Rapamycin Derivatives For The Treatment And/Or Prevention Of Cardiovas Cular Disorders
EP1933845A2 (en) * 2005-08-25 2008-06-25 Medtronic Vascular, Inc. Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
EP1940481B1 (en) * 2005-08-25 2015-01-14 Medtronic Vascular, Inc. Medical devices and coatings therefore comprising biodegradable polymers with enhanced functionality
JP5285426B2 (en) * 2005-10-14 2013-09-11 アボット ラボラトリーズ Compositions, systems, kits and methods for administering a rapamycin analog with paclitaxel using a medical device
WO2007054183A1 (en) * 2005-11-10 2007-05-18 Schering Aktiengesellschaft Reduction of restenosis
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
BRPI0600275A (en) * 2006-01-03 2007-10-02 Brz Biotecnologia Ltda Coronary prosthesis releasing drug composition for prevention and treatment of restenosis and manufacturing process
BRPI0600285C1 (en) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda nanoparticulate pharmaceutical compounds useful for treating restenosis
US20080003254A1 (en) * 2006-05-23 2008-01-03 Abbott Laboratories Systems and methods for delivering a rapamycin analog that do not inhibit human coronary artery endothelial cell migration
US8323676B2 (en) * 2008-06-30 2012-12-04 Abbott Cardiovascular Systems Inc. Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
US20090258028A1 (en) * 2006-06-05 2009-10-15 Abbott Cardiovascular Systems Inc. Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
JP2010500286A (en) * 2006-07-25 2010-01-07 アボット・ラボラトリーズ Crystal form of rapamycin analog
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2068911A4 (en) * 2006-09-13 2011-08-03 Arca Biopharma Inc METHODS OF TREATING CANCER
EP2083834B1 (en) 2006-09-13 2017-06-21 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US8690823B2 (en) 2007-07-13 2014-04-08 Abbott Cardiovascular Systems Inc. Drug coated balloon catheter
US8617114B2 (en) * 2007-07-13 2013-12-31 Abbott Cardiovascular Systems Inc. Drug coated balloon catheter
US8765162B2 (en) 2008-06-30 2014-07-01 Abbott Cardiovascular Systems Inc. Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
US20100047319A1 (en) * 2008-08-21 2010-02-25 Michael Huy Ngo Biodegradable Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices With Enhanced Bioabsorption Times
US8092822B2 (en) 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CA2745238A1 (en) 2008-12-02 2010-06-10 Biocompatibles Uk Limited Pancreatic tumour treatment
WO2010066049A1 (en) * 2008-12-11 2010-06-17 The Govenors Of The University Of Alberta Methods and systems for inducing immunologic tolerance to non-self antigens
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010135352A1 (en) 2009-05-18 2010-11-25 Pneumrx, Inc. Cross-sectional modification during deployment of an elongate lung volume reduction device
US20100324645A1 (en) * 2009-06-17 2010-12-23 John Stankus Drug coated balloon catheter and pharmacokinetic profile
US8828474B2 (en) * 2009-09-20 2014-09-09 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US8389041B2 (en) 2010-06-17 2013-03-05 Abbott Cardiovascular Systems, Inc. Systems and methods for rotating and coating an implantable device
US8632846B2 (en) * 2010-09-17 2014-01-21 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
CN101947350A (en) * 2010-10-27 2011-01-19 上海硕创生物医药科技有限公司 Eccentric hollow balloon catheter
KR102343212B1 (en) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
US10517892B2 (en) 2013-10-22 2019-12-31 Medtronic Minimed, Inc. Methods and systems for inhibiting foreign-body responses in diabetic patients
CN108601802A (en) 2015-12-02 2018-09-28 纪念斯隆-凯特林癌症中心 Sai Nika paddy viruses（SVV）The oncotherapy of cell receptor targeting
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
CN105943209A (en) * 2016-06-08 2016-09-21 葛晨亮 Novel drug-coated balloon
CN108187212B (en) * 2018-03-14 2022-07-15 董鹏 Medicine balloon
AU2020315800A1 (en) 2019-07-19 2022-03-03 Seneca Therapeutics, Inc. Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
CN114146231A (en) * 2020-09-07 2022-03-08 上海鸿脉医疗科技有限公司 Drug balloon and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
WO2001087372A1 (en) * 2000-05-12 2001-11-22 Cordis Corporation Drug combinations useful for prevention of restenosis
WO2002066092A2 (en) * 2001-02-23 2002-08-29 Angiogene Inc. Drug eluting device for treating vascular diseases
EP1236478A1 (en) * 2001-02-27 2002-09-04 Medtronic Ave, Inc. Peroxisome proliferator-activated receptor gamma ligand eluting medical device

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5527337A (en) 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US4916193A (en) * 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5283201A (en) * 1988-05-17 1994-02-01 Advanced Power Technology, Inc. High density power device fabrication process
US5092877A (en) * 1988-09-01 1992-03-03 Corvita Corporation Radially expandable endoprosthesis
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5202750A (en) * 1990-04-09 1993-04-13 U.S. Philips Corp. MOS-gated thyristor
WO1991017724A1 (en) * 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
JPH04230389A (en) 1990-07-16 1992-08-19 American Home Prod Corp Rapamycin derivative
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US6248129B1 (en) * 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
PT98990A (en) 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US6090901A (en) * 1991-07-05 2000-07-18 Biocompatibles Limited Polymeric surface coatings
US5705583A (en) * 1991-07-05 1998-01-06 Biocompatibles Limited Polymeric surface coatings
US5457111A (en) 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
CA2094858C (en) * 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
US5283456A (en) * 1992-06-17 1994-02-01 International Business Machines Corporation Vertical gate transistor with low temperature epitaxial channel
ZA935111B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
US5449382A (en) * 1992-11-04 1995-09-12 Dayton; Michael P. Minimally invasive bioactivated endoprosthesis for vessel repair
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5324673A (en) * 1992-11-19 1994-06-28 Motorola, Inc. Method of formation of vertical transistor
US5322802A (en) * 1993-01-25 1994-06-21 North Carolina State University At Raleigh Method of fabricating silicon carbide field effect transistor
WO1994021308A1 (en) * 1993-03-18 1994-09-29 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
US5824048A (en) * 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
JPH07122749A (en) * 1993-09-01 1995-05-12 Toshiba Corp Semiconductor device and manufacturing method thereof
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
KR0141218B1 (en) * 1993-11-24 1998-07-15 윤종용 Fabrication method of semkonductor device
US5641694A (en) * 1994-12-22 1997-06-24 International Business Machines Corporation Method of fabricating vertical epitaxial SOI transistor
FR2730231B1 (en) * 1995-02-02 1997-04-04 Fournier Sca Lab COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5637898A (en) * 1995-12-22 1997-06-10 North Carolina State University Vertical field effect transistors having improved breakdown voltage capability and low on-state resistance
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
JP4052395B2 (en) * 1996-06-04 2008-02-27 クック インコーポレーティッド． Insertable medical device
EP1208847B8 (en) * 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
AU746984B2 (en) 1997-03-31 2002-05-09 Kabushikikaisha Igaki Iryo Sekkei Stent for vessels
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
JP4042162B2 (en) * 1997-04-17 2008-02-06 東洋紡績株式会社 Biocompatible polymer
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
TW557297B (en) * 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US6623521B2 (en) * 1998-02-17 2003-09-23 Md3, Inc. Expandable stent with sliding and locking radial elements
US6096726A (en) * 1998-03-11 2000-08-01 Surface Solutions Laboratories Incorporated Multicomponent complex for use with substrate
DK1064942T3 (en) * 1998-03-26 2004-11-01 Fujisawa Pharmaceutical Co Sustained release preparation of a macrolide
WO1999049908A1 (en) * 1998-03-31 1999-10-07 University Of Cincinnati Temperature controlled solute delivery system
US20010029351A1 (en) * 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
WO1999055396A1 (en) * 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
US6104045A (en) * 1998-05-13 2000-08-15 Micron Technology, Inc. High density planar SRAM cell using bipolar latch-up and gated diode breakdown
US6225165B1 (en) * 1998-05-13 2001-05-01 Micron Technology, Inc. High density SRAM cell with latched vertical transistors
US6280411B1 (en) * 1998-05-18 2001-08-28 Scimed Life Systems, Inc. Localized delivery of drug agents
US6229161B1 (en) * 1998-06-05 2001-05-08 Stanford University Semiconductor capacitively-coupled NDR device and its applications in high-density high-speed memories and in power switches
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
CA2340652C (en) * 1998-08-20 2013-09-24 Cook Incorporated Coated implantable medical device comprising paclitaxel
US6033562A (en) * 1998-08-28 2000-03-07 Budeit; Donald A Apparatus for aerating wastewater from pressurized or gravity flow sources
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US6187024B1 (en) * 1998-11-10 2001-02-13 Target Therapeutics, Inc. Bioactive coating for vaso-occlusive devices
US6419692B1 (en) * 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6730349B2 (en) * 1999-04-19 2004-05-04 Scimed Life Systems, Inc. Mechanical and acoustical suspension coating of medical implants
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6607598B2 (en) * 1999-04-19 2003-08-19 Scimed Life Systems, Inc. Device for protecting medical devices during a coating process
WO2001001957A1 (en) * 1999-05-27 2001-01-11 Biocompatibles Limited Local drug delivery
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6713119B2 (en) * 1999-09-03 2004-03-30 Advanced Cardiovascular Systems, Inc. Biocompatible coating for a prosthesis and a method of forming the same
US6077733A (en) * 1999-09-03 2000-06-20 Taiwan Semiconductor Manufacturing Company Method of manufacturing self-aligned T-shaped gate through dual damascene
US6663606B1 (en) * 1999-10-28 2003-12-16 Scimed Life Systems, Inc. Biocompatible medical devices
US6899731B2 (en) * 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
SE0000363A0 (en) * 2000-02-04 2001-08-05 Zoucas Kirurgkonsult Ab Coated medical device
WO2001063416A1 (en) * 2000-02-24 2001-08-30 Bops Incorporated Methods and apparatus for scalable array processor interrupt detection and response
US20020013616A1 (en) * 2000-05-05 2002-01-31 Andrew Carter Multilayer stents having enhanced flexibility and hoop strength
US20020007214A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020007213A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020005206A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Antiproliferative drug and delivery device
US20020007215A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
EP1301221B1 (en) * 2000-05-16 2006-02-15 Ortho-McNeil Pharmaceutical, Inc. Process for coating medical devices using super-critical carbon dioxide
US20020077693A1 (en) * 2000-12-19 2002-06-20 Barclay Bruce J. Covered, coiled drug delivery stent and method
US6974473B2 (en) * 2000-06-30 2005-12-13 Vascular Architects, Inc. Function-enhanced thrombolytic AV fistula and method
US6506408B1 (en) * 2000-07-13 2003-01-14 Scimed Life Systems, Inc. Implantable or insertable therapeutic agent delivery device
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
AU9486901A (en) * 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US6746773B2 (en) * 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
AU1129902A (en) * 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US6758859B1 (en) * 2000-10-30 2004-07-06 Kenny L. Dang Increased drug-loading and reduced stress drug delivery device
AU2002239436B2 (en) * 2000-10-31 2007-04-26 Cook Medical Technologies Llc Coated implantable medical device
US6517888B1 (en) * 2000-11-28 2003-02-11 Scimed Life Systems, Inc. Method for manufacturing a medical device having a coated portion by laser ablation
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
EP1355588B1 (en) * 2000-12-22 2007-08-15 Avantec Vascular Corporation Device for delivery of therepeutic agents
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
ATE481097T1 (en) * 2001-01-16 2010-10-15 Vascular Therapies Llc IMPLANTABLE DEVICE CONTAINING ABSORBABLE MATRIX MATERIAL AND ANTIPROLIFERATIVE ACTIVES FOR PREVENTING OR TREATING FAILURE OF VASCULAR HEMODIALYSIS APPROACHES AND OTHER VASCULAR TRANSPLANTS
US6752829B2 (en) * 2001-01-30 2004-06-22 Scimed Life Systems, Inc. Stent with channel(s) for containing and delivering a biologically active material and method for manufacturing the same
DE10107795B4 (en) * 2001-02-13 2014-05-15 Berlex Ag Vascular support with a basic body, method for producing the vascular support, apparatus for coating the vascular support
US6462359B1 (en) * 2001-03-22 2002-10-08 T-Ram, Inc. Stability in thyristor-based memory device
US6780424B2 (en) * 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US6787179B2 (en) * 2001-06-29 2004-09-07 Ethicon, Inc. Sterilization of bioactive coatings
EP1273314A1 (en) * 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
US6805703B2 (en) * 2001-09-18 2004-10-19 Scimed Life Systems, Inc. Protective membrane for reconfiguring a workpiece
US6669980B2 (en) * 2001-09-18 2003-12-30 Scimed Life Systems, Inc. Method for spray-coating medical devices
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7033389B2 (en) * 2001-10-16 2006-04-25 Scimed Life Systems, Inc. Tubular prosthesis for external agent delivery
US6764709B2 (en) * 2001-11-08 2004-07-20 Scimed Life Systems, Inc. Method for making and measuring a coating on the surface of a medical device using an ultraviolet laser
US6517889B1 (en) * 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
US7014654B2 (en) * 2001-11-30 2006-03-21 Scimed Life Systems, Inc. Stent designed for the delivery of therapeutic substance or other agents
US6945994B2 (en) * 2001-12-05 2005-09-20 Boston Scientific Scimed, Inc. Combined balloon-expanding and self-expanding stent
TW200306826A (en) * 2002-01-10 2003-12-01 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
US6743463B2 (en) * 2002-03-28 2004-06-01 Scimed Life Systems, Inc. Method for spray-coating a medical device having a tubular wall such as a stent
US20030204168A1 (en) * 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US7754238B2 (en) * 2002-05-03 2010-07-13 Avi Biopharma, Inc. Delivery of microparticle-conjugated drugs for inhibition of stenosis
US7396539B1 (en) * 2002-06-21 2008-07-08 Advanced Cardiovascular Systems, Inc. Stent coatings with engineered drug release rate
US20050019404A1 (en) * 2003-06-30 2005-01-27 Hsing-Wen Sung Drug-eluting biodegradable stent
US6945995B2 (en) * 2002-08-29 2005-09-20 Boston Scientific Scimed, Inc. Stent overlap point markers
US7302690B2 (en) * 2003-07-31 2007-11-27 International Business Machines Corporation Method and apparatus for transparently sharing an exception vector between firmware and an operating system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
WO2001087372A1 (en) * 2000-05-12 2001-11-22 Cordis Corporation Drug combinations useful for prevention of restenosis
WO2002066092A2 (en) * 2001-02-23 2002-08-29 Angiogene Inc. Drug eluting device for treating vascular diseases
EP1236478A1 (en) * 2001-02-27 2002-09-04 Medtronic Ave, Inc. Peroxisome proliferator-activated receptor gamma ligand eluting medical device

Also Published As

Publication number Publication date
WO2003022807A2 (en) 2003-03-20
EP1578705A2 (en) 2005-09-28
CN101564571B (en) 2017-02-22
EP2255836A2 (en) 2010-12-01
PL374776A1 (en) 2005-10-31
US20080153790A1 (en) 2008-06-26
CN101564571A (en) 2009-10-28
US20060198870A1 (en) 2006-09-07
ATE476401T1 (en) 2010-08-15
CN100548236C (en) 2009-10-14
CN1635857A (en) 2005-07-06
US20090047323A1 (en) 2009-02-19
EP1578705B1 (en) 2010-08-04
US20030129215A1 (en) 2003-07-10
DE60237241D1 (en) 2010-09-16
JP2006504441A (en) 2006-02-09
US20090162413A1 (en) 2009-06-25
WO2003022807A8 (en) 2003-12-11
EP2255836A3 (en) 2011-04-06
HK1085723A1 (en) 2006-09-01
EP2255836B1 (en) 2014-11-12
CA2460074C (en) 2013-10-22
BRPI0212433A2 (en) 2007-04-10
US20090047324A1 (en) 2009-02-19
BRPI0212433A8 (en) 2018-05-08
CA2460074A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
WO2003022807A3 (en) Medical devices containing rapamycin analogs
WO2006050170A3 (en) Medical devices containing rapamycin analogs
WO2008063319A3 (en) Methods of administering rapamycin analogs with anti-inflammatories using medical devices
WO2007047473A3 (en) Methods of administering rapamycin analogs with anti-inflammatories using medical devices
WO2007111925A3 (en) Zotarolimus-containing drug delivery systems for implantation into a body lumen of a subject
WO2008045961A3 (en) Compositions and methods of administering rapamycin analogs with paclitaxel using medical devices
EP2258415A3 (en) Medical devices containing rapamycin analogs
WO2008021124A3 (en) Compositions and drug-delivery systems comprising rapamycin analogs and paclitaxel
AU2003258331A1 (en) Drug eluting coatings for medical implants
JP2006504441A5 (en)
WO2005086831A3 (en) Endothelial ligand binding coated medical device
ATE305803T1 (en) RELEASE OF ACTIVE INGREDIENTS USING THERAPEUTIC HYDROGELS
ATE298592T1 (en) DRUG COMBINATIONS FOR RESTENosis PREVENTION
WO2005051456A3 (en) Composition and apparatus for transdermal delivery
EP1832301A3 (en) Coatings for implantable medical devices
WO2001087342A3 (en) Delivery devices for treatment of vascular disease
WO2004000379A8 (en) Stent coatings with sustained drug release rate
NO953278L (en) Methods for in vivo delivery of biologically active substances and compositions useful for this purpose
WO2004045578A3 (en) Drug delivery system
WO2007032777A3 (en) Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
RU2005133199A (en) DEVICES, METHODS AND COMPOSITIONS FOR PREVENTING RESTENOSIS
JP2006523235A5 (en)
TW200730171A (en) Compositions and methods of administering rapamycin analogs with paclitaxel using medical devices
TW200731960A (en) Methods of administering rapamycin analogs with anti-inflammatories using medical devices
TW200716086A (en) Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 12/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "10/235,572"

WWE Wipo information: entry into national phase

Ref document number: 10488815

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003526883

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 374776

Country of ref document: PL

Ref document number: 2460074

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002330012

Country of ref document: AU

Ref document number: 00194/MUMNP/2004

Country of ref document: IN

Ref document number: 194/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002766269

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028217527

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002766269

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0212433

Country of ref document: BR